Sacubitril/valsartan (LCZ696)

Name: Sacubitril/valsartan (LCZ696)
Brand: Selleck Chemicals
SKU: S7678
Rating: 5 (3 reviews)

For research use only.

Catalog No.S7678 Synonyms: Sacubitril, Valsartan

3 publications

Sacubitril/valsartan (LCZ696) Chemical Structure

CAS No. 936623-90-4

Sacubitril/valsartan (LCZ696, Sacubitril, Valsartan), consisting of valsartan and sacubitril in 1:1 molar ratio, is an orally bioavailable, dual-acting angiotensin receptor-neprilysin inhibitor (ARNi) for hypertension and heart failure. Phase 3.

Selleck's Sacubitril/valsartan (LCZ696) has been cited by 3 publications

J Mol Cell Cardiol, 2017, 108:138-148

PubMed: 28623750 ( click the link to review the publication )

RSC Adv, 2017, 29170-29183

PubMed: None ( click the link to review the publication )

RSC Adv, 2017, 10.1039/C7RA01404J

PubMed: ( click the link to review the publication )

2 Customer Reviews

Histological analysis staining of three groups. (a) Representative H&E-staining micrographs displaying transverse myocardial section (original magnification ×200). (b) Masson staining of three groups (original magnification ×200). Collagen content (%) of heart tissues were presented as fibrosis (***P < 0.001, n = 7 per group). (c) Cardiac section of three group mice hearts stained with WGA (original magnification ×400) (*P < 0.05, n = 7 per group). (d) The expression of Drp1 significantly increased in DOX group (***P < 0.001, n = 7 per group) and it decreased in DOX + LCZ696 group (**P < 0.01, n = 7 per group).

J Mol Cell Cardiol, 2017, 108:138-148. Sacubitril/valsartan (LCZ696) purchased from Selleck.

Representative H&E stain of heart sections from (A) sham-operated group, (B) model group, (C) LCZ696-treated group. Representative H&E-staining micrographs displaying transverse myocardial section (original magnification ×100).

RSC Adv, 2017, doi:10.1039/C7RA01404J. Sacubitril/valsartan (LCZ696) purchased from Selleck.

Purity & Quality Control

Choose Selective Neprilysin Inhibitors

Biological Activity

Description

Sacubitril/valsartan (LCZ696, Sacubitril, Valsartan), consisting of valsartan and sacubitril in 1:1 molar ratio, is an orally bioavailable, dual-acting angiotensin receptor-neprilysin inhibitor (ARNi) for hypertension and heart failure. Phase 3.

Targets

RAAS ^[1]

Assay

Methods	Test Index	PMID
Western blot	p-AMPKα / AMPKα / p-AKT / AKT / p-eNOS / eNOS ; PubMed: 28178430 Bosn J Basic Med Sci Effects of valsartan (10 µmol/L) on Akt, adenosine monophosphate-activated protein kinase (AMPK) and endothelial nitric oxide synthase (eNOS) phosphorylation and expression in human umbilical vein endothelial cells. Ctrl: control; Antibodies: p-AMPKα (Thr172) - phospho-AMPKα (Thr172), AMPKα, p-Akt (Ser473) - phospho-Akt (Ser473), Akt, p-eNOS (Ser1177) - phospho-eNOS (Ser1177), eNOS, and beta-actin. p-LKB1 / t-LKB1 / p-AMPK / t-AMPK / p-ACC / t-ACC ; PubMed: 25109475 J Cell Mol Med To confirm that valsartan activates AMPK through LKB1, THP-1 cells were transfected with LKB1 siRNA or scrambled siRNA and incubated with valsartan for 24 hrs. The proteins were quantified and Western blot analysis was performed with corresponding antibodies (P-AMPK, AMPK, p-LKB1, LKB1, p-ACC and ACC). The relative intensity of each protein is depicted as bar graphs on the right side	28178430 25109475

In vivo

In double-transgenic rats overexpressing human renin and angiotensinogen and plasma atrial natriuretic peptide immunoreactivity, LCZ696 (60 mg/kg p.o.) induces a dose-dependent and long-lasting reduction in mean arterial pressure (MAP), and stimulates a rapid and dose-dependent augmentation of plasma ANP immunoreactivity. ^[1] In rat myocardial infarction (MI) model, LCZ696 (68 mg/kg p.o.) attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy. ^[2]

Protocol

Animal Research: ^[2]	- Collapse Animal Models: Double-transgenic rats overexpressing human renin and angiotensinogen and plasma atrial natriuretic peptide immunoreactivity Dosages: ~60 mg/kg Administration: p.o. (Only for Reference)

References

Solubility (25°C)

In vitro	Water	100 mg/mL warmed (109.17 mM)
	DMSO	30 mg/mL warmed (32.75 mM)
	Ethanol	''9 mg/mL warmed

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Sacubitril/valsartan (LCZ696) SDF

Molecular Weight	915.98
Formula	C₂₄H₂₉N₅O₃.C₂₄H₂₉NO₅.5/2H₂O.3Na
CAS No.	936623-90-4
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	Sacubitril, Valsartan
Smiles	[Na+].[Na+].[Na+].CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NN=N[NH]3)C(C(C)C)C(O)=O.CCOC(=O)C(C)CC(CC4=CC=C(C=C4)C5=CC=CC=C5)NC(=O)CCC(O)=O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

g

Dosing volume per animal

ul

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-05-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02690974	Completed	Drug: LCZ696 (sacubitril/valsartan)	Hearth Failure With Reduced Ejection Fraction (HFrEF)	Novartis Pharmaceuticals\|Novartis	March 8 2016	Phase 4
NCT02661217	Completed	Drug: LCZ696	Heart Failure With Reduced Ejection Fraction	Novartis Pharmaceuticals\|Novartis	February 12 2016	Phase 4
NCT02226120	Completed	Drug: LCZ696	Chronic Heart Failure With Reduced Ejection Fraction	Novartis Pharmaceuticals\|Novartis	October 16 2014	Phase 3

Choose Your Country or Region

By Signaling Pathways

By product type

Sacubitril/valsartan (LCZ696)